Goldman Sachs: Assigned a "Buy" rating to SKB BIO-B (06990) with a Target Price of HK$239.14.

The bank expects SKB264 (TROP2ADC) to become a key driving force for the future growth of Kelun-Botai.

Zhitong FinanceMar 13 22:13 ET

Private Companies Invested in Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Copped the Brunt of Last Week's HK$3.1b Market Cap Decline

Simply Wall StMar 13 21:11 ET

SKB BIO-B (06990.HK) plans to hold a Board of Directors meeting on March 24 to approve the annual performance.

Gelonghui, March 12 - SKB BIO-B (06990.HK) announced that the Board of Directors has scheduled a board meeting on Monday, March 24, 2025, to consider and approve the company's and its subsidiaries' annual performance for the year ending December 31, 2024, and its release, as well as to address other matters.

Gelonghui FinanceMar 12 05:05 ET

SKB BIO-B: NOTICE OF BOARD MEETING

HKEXMar 12 05:01 ET · Announcements

SKB Biopharma Gets Marketing Go-Ahead for Second Indication of Cancer Drug

MT NewswiresMar 11 02:07 ET

Express News | Sichuan Kelun-Biotech Biopharmaceutical - Core Product Sacituzumab Tirumotecan (Sac-TMT) Approved for Marketing for Second Indication by Nmpa

ReutersMar 10 04:45 ET